Modeled indirect comparison suggests DFS benefit for pembrolizumab-belzutifan vs surveillance in RCC

Retrospective · Clin Genitourin Cancer · 2026-10-07. Number 4 in the UrologyWatch Top 5 for October 7, 2026.

An anchored indirect comparison using KEYNOTE-564 and LITESPARK-022 data estimated a DFS hazard ratio of 0.52 (95% CI 0.39-0.68) for adjuvant pembrolizumab plus belzutifan versus surveillance after nephrectomy for clear cell RCC. This is a modeled, not head-to-head, comparison.

Why it matters: Modeling suggests a possible risk-adapted approach to weigh added toxicity against estimated DFS benefit when considering belzutifan addition post-nephrectomy, pending direct trial confirmation.

Source: Clin Genitourin Cancer · PubMed 42838824 · DOI 10.1016/j.clgc.2026.102679

The full October 7, 2026 edition · Today's urology news